TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16334719
Drug: Zishen Tongli
Normalized name: ALCOHOL 42 mL in 60 mL TOPICAL GEL [TongYi CleanGuard Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zishen Tongli Jiaonang (capsules for nourishing the kidney and promoting urination)
Study: 16334719
Drug: Antibiotics according
Normalized name: clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotics according to drug sensitive tests (control group)
Study: 28692407
Drug: Residential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residential treatment
Study: 19015420
Drug: Indigo naturalis
Normalized name: indigo
DrugBank: Indigo (DB16862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indigo naturalis ointment
Study: 10711101
Drug: Regular daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular daily telephone call reminders
Study: 10711101
Drug: Daily videotelephone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily videotelephone call reminders
Study: 7477807
Drug: Vitamin supplementation
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin supplementation (10 times the recommended daily dose of 9 vitamins)
Study: 8724065
Drug: Pneumococcal glycoprotein
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal glycoprotein conjugate vaccine (primary immunization)
Study: 8724065
Drug: Pneumococcal polysaccharide
Normalized name: pneumococcal polysaccharides (23)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal polysaccharide vaccine (secondary immunization)
Study: 1929247
Drug: Amoxicillin-clavulanate, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate, 1 g plus 250 mg per os every 12 h for 3 days
Study: 1929247
Drug: Amoxicillin-clavulanate, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate, 1 g plus 250 mg per os every 12 h on day 3 only (1-day regimen)
Study: 29973284
Drug: High-dose JWYH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose JWYH plus usual care
Study: 29973284
Drug: Low-dose JWYH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose JWYH plus usual care
Study: 26277174
Drug: HILT laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: HILT laser therapy
Study: 20936417
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 mg, twice daily)
Study: 19003734
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg vitamin C supplementation
Study: 3886142
Drug: Guanfacine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (1 mg/day, once daily)
Study: 3886142
Drug: Guanfacine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (2.5 mg/day, once daily)
Study: 3886142
Drug: Methyldopa (763
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (763 mg/day, twice daily)
Study: 3886142
Drug: Guanfacine (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (continued therapy for one year)
Study: 29628009
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of aprotinin
Study: 18517077
Drug: Oral fexofenadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fexofenadine (180 mg)
Study: 18517077
Drug: Oral diphenhydramine
Normalized name: diphenhydramine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diphenhydramine (50 mg)
Study: 18517077
Drug: Intramuscular diphenhydramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular diphenhydramine (50 mg)
Study: 16043675
Drug: Testosterone patch
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone patch 300 microg/d
Study: 16043675
Drug: Testosterone patch
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone patch 150 microg/d
Study: 16043675
Drug: Testosterone patch
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone patch 450 microg/d
Study: 12427118
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human enzyme, alpha-galactosidase A (r-halalphaGalA), administered IV at 1 mg/kg biweekly for 11 months
Study: 482028
Drug: Intradimensional oddity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradimensional oddity shift (CC group)
Study: 31646969
Drug: PGB diluted
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGB diluted with 0.5 mL mepivacaine 1% and long 19G needle
Study: 31646969
Drug: PGB diluted
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGB diluted with 0.5 mL mepivacaine 1% and short 21G needle
Study: 25816805
Drug: 1.7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.7 g n‐3 PUFA daily for 3 months
Study: 17701133
Drug: Rebamipide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide (100 mg for 7 weeks)
Study: 15251636
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy aiming for strict normoglycemia (80 to 110 mg/dL or 4.5 to 6.1 mmol/L) during intensive care
Study: 11054443
Drug: Antibiotic regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic regimen A
Study: 11054443
Drug: Antibiotic regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic regimen B
Study: 8455332
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg OFLX once daily
Study: 8455332
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg OFLX three times daily
Study: 3513519
Drug: Verapamil (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (120 to 240 mg 2 times a day)
Study: 3513519
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 to 240 mg 2 times a day)
Study: 3513519
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (Verapamil and Propranolol)
Study: 31515458
Drug: Anti-EGFR antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-EGFR antibody treatment (n = 12 class 2, n = 28 class 3)
Study: 31515458
Drug: First- or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: First- or second-line anti-EGFR therapy
Study: 31515458
Drug: Third- or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third- or later-line anti-EGFR therapy
Study: 28095527
Drug: One dental
Normalized name: carbenoxolone Dental Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dental implant
Study: 28095527
Drug: Two dental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two dental implants
Study: 28095527
Drug: One or
Normalized name: Geone Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: One or two dental implants
Study: 12006526
Drug: Anthracycline-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline-based therapy (HEC)
Study: 12006526
Drug: Anthracycline-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline-based therapy (EC)
Study: 9819447
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b plus ribavirin (1000 to 1200 mg orally per day for six months)
Study: 7667050
Drug: Clarithromycin suspension
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin suspension 15 mg/kg/day divided twice a day
Study: 7667050
Drug: Erythromycin suspension
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin suspension 40 mg/kg/day divided twice or three times a day
Study: 2468932
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg SK&F 86466
Study: 2468932
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg SK&F 86466
Study: 2468932
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg SK&F 86466
Study: 21288351
Drug: Sevelamer carbonate
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer carbonate (1600 mg with meals for 4 weeks, then randomized to continue for 36 weeks)
Study: 18727661
Drug: On‐St group
Approvals — FDA: no, EMA: no, PMDA: no
Description: On‐St group (patients on steroids at 15th day after transplantation)
Study: 18727661
Drug: Off‐St group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Off‐St group (patients not on steroids at 15th day after transplantation)
Study: 16452695
Drug: Assertive Community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertive Community Treatment
Study: 15323594
Drug: Fluoxetine dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine dose increase
Study: 15323594
Drug: Lithium augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium augmentation of fluoxetine
Study: 15323594
Drug: Desipramine augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine augmentation of fluoxetine
Study: 11732814
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide nasal spray (IBNS) 80 microg twice per day (b.i.d.)
Study: 9417265
Drug: NaCl bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl bolus injection (20 ml)
Study: 9417265
Drug: Body mass
Normalized name: Total Body Massager Item
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body mass index, injection flow, and contrast material volume
Study: 7525120
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily GH injection (3 IU/m2/24 h in the evening)
Study: 7525120
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily GH injections (3 IU/m2, two-thirds in the evening and one-third in the morning)
Study: 7525120
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily GH injection
Study: 7525120
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily GH injections
Study: 3116111
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of paracetamol
Study: 3116111
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of diflunisal
Study: 3116111
Drug: First and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: First and second doses of paracetamol
Study: 3116111
Drug: First and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: First and second doses of diflunisal
Study: 27659879
Drug: CSL112 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL112 (2 g)
Study: 19038899
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 or 400 mg daily)
Study: 10871568
Drug: Carb +
Normalized name: Carb-O-Lac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carb + Pro trial (0.8 g carbohydrate*kg(‐)(1)*h(‐)(1) plus 0.4 g wheat protein hydrolysate plus free leucine and phenylalanine*kg(‐)(1)*h(‐)(1))
Study: 10871568
Drug: Carb +
Normalized name: Carb-O-Lac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carb + Carb trial (1.2 g carbohydrate*kg(‐)(1)*h(‐)(1))
Study: 10871568
Drug: Carb trial
Normalized name: Carb-O-Lac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carb trial (0.8 g carbohydrate*kg(‐)(1)*h(‐)(1))
Study: 8804876
Drug: Interferon-alpha-2b, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha-2b, 3 MU thrice weekly for 6 months (n = 26)
Study: 8804876
Drug: Interferon-alpha-2b, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha-2b, 3 MU thrice weekly for 12 months (n = 34)
Study: 8804876
Drug: Interferon-alpha-2b, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha-2b, 3 MU thrice weekly for 6 months
Study: 8804876
Drug: Interferon-alpha-2b, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha-2b, 3 MU thrice weekly for 12 months
Study: 31128228
Drug: Elevated ANP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated ANP, BNP, or Pro‐BNP (cutoffs of >77, 100, and 900 pg/mL, respectively)
Study: 11072435
Drug: 15-mg nicotine
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15-mg nicotine patch (Nicotrol)
Study: 11072435
Drug: 21-mg nicotine
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 21-mg nicotine patch (Nicoderm)
Study: 11072435
Drug: Both nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both nicotine patches (Nicotrol and Nicoderm)
Study: 7540147
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy (historical control group)
Study: 2025787
Drug: Gemfibrozil treatment
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil treatment for 12 months
Study: 6617110
Drug: Hydrochlorothiazide-spironolactone combination
Normalized name: hydrochlorothiazide / spironolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide-spironolactone combination (25 mg B.I.D.)
Study: 6617110
Drug: Hydrochlorothiazide-spironolactone combination
Normalized name: hydrochlorothiazide / spironolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide-spironolactone combination (50 mg O.I.D.)
Study: 30022362
Drug: IV paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV paracetamol 1000 mg in 100 ml solution (Group P)
Study: 30022362
Drug: IV ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV ibuprofen 800 mg in 100 ml saline (Group I)
Study: 30022362
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group C, 100 ml saline solution)
Study: 18848553
Drug: adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: adalimumab 40 mg weekly
Study: 18848553
Drug: adalimumab combined
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: adalimumab combined (every other week and weekly)
Study: 18848553
Drug: adalimumab weekly
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: adalimumab weekly
Study: 16038684
Drug: NK1 antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: NK1 antagonist GR205171 (5 mg)
Study: 12871686
Drug: Nicorandil (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (80 g/kg intravenous injection 5 min before ballooning)
Study: 10475141
Drug: Clinda‐saar 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinda‐saar 600 (test preparation, 600 mg clindamycin)
Study: 10475141
Drug: Sobelin 300
Normalized name: lobeline
DrugBank: Lobeline (DB05137)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sobelin 300 (reference preparation, 300 mg clindamycin)
Study: 1831340
Drug: Single-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intravenous administration of CI-898 at 15 mg/m2
Study: 1831340
Drug: 5-day intravenous
Normalized name: ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-day intravenous administration of CI-898 starting at 10 mg/m2/day
Study: 1831340
Drug: 5-day intravenous
Normalized name: ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-day intravenous administration of CI-898
Study: 1831340
Drug: Single treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment of CI-898
Study: 1831340
Drug: 5-day treatment
Normalized name: 30 day Acne Treatment Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day treatment of CI-898
Study: 29901443
Drug: Drug‐eluting stents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug‐eluting stents with bioabsorbable polymers (BP‐DES)
Study: 27598678
Drug: BDP/FF/GB (beclometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF/GB (beclometasone dipropionate 100 μg, formoterol fumarate 6 μg, glycopyrronium bromide 12.5 μg)
Study: 27598678
Drug: BDP/FF (beclometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF (beclometasone dipropionate 100 μg, formoterol fumarate 6 μg)
Study: 22515897
Drug: NovaMin paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: NovaMin paste treatment for 5 minutes (Group A)
Study: 20560802
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg daily for a maximum of 4 weeks)
Study: 20560802
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (pain-relieving therapy only)
Study: 17697874
Drug: Tesaglitazar 3
Normalized name: Tesaglitazar
DrugBank: Tesaglitazar (DB06536)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tesaglitazar 3 mg
Study: 15578172
Drug: S‐omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐omeprazole (20 mg)
Study: 15578172
Drug: R‐omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: R‐omeprazole (20 mg)
Study: 15578172
Drug: Racemic omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Racemic omeprazole (20 mg)
Study: 15578172
Drug: S‐omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐omeprazole (40 mg)
Study: 15578172
Drug: R‐omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: R‐omeprazole (40 mg)
Study: 15578172
Drug: Racemic omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Racemic omeprazole (40 mg)
Study: 9933654
Drug: 153Sm-EDTMP at
Normalized name: 153SM-EDTMP
DrugBank: Samarium (153Sm) lexidronam (DB05273)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 153Sm-EDTMP at a dose of 37 MBq/kg (group I)
Study: 9933654
Drug: 153Sm-EDTMP at
Normalized name: 153SM-EDTMP
DrugBank: Samarium (153Sm) lexidronam (DB05273)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 153Sm-EDTMP at a dose of 18.5 MBq/kg (group II)
Study: 12690546
Drug: Piperacillin-tazobactam (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam (4.5 g every 8 h)
Study: 12690546
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g once daily plus gentamicin 5 mg/kg once daily)
Study: 1489202
Drug: 1-hour infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour infusions of amphotericin B (AMB) at doses ranging from 0.27 to 0.89 mg/kg
Study: 1489202
Drug: 1-hour infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour infusions of amphotericin B (AMB)
Study: 26372517
Drug: Bifidobacterium animalis
Normalized name: Bifidobacterium Animalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium animalis subsp. lactis BB-12 (BB-12) administered twice a day (daily dose of BB-12 10 billion colony-forming units) until the age of 2 years.
Study: 25981123
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (±glulisine)
Study: 16707077
Drug: Glycerol trinitrate
Normalized name: Glycerol trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol trinitrate (GTN) patches
Study: 16707077
Drug: Standard beta2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard beta2 agonist
Study: 15265423
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with omeperazole, clarithromycin (CLA), and amoxycillin (AMO) for one week (CLA group)
Study: 15265423
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with omeperazole, metronidazole (MET), and amoxycillin (AMO) for two weeks (MET group)
Study: 15265423
Drug: Re-treatment with
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-treatment with CLA triple therapy for one week after failure of MET therapy
Study: 15265423
Drug: Re-treatment with
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-treatment with increased doses of CLA and longer treatment course after failure of CLA therapy
Study: 15265423
Drug: Tetra therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetra therapy with omeperazole, colloidal bismuth subcitrate (CBS), furazolidone (FUR), and AMO after failure of re-treatment
Study: 15265423
Drug: CLA triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLA triple therapy for children who were Hp eradicated and followed for 3 years
Study: 8028874
Drug: Medications with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications with hyaluronidase
Study: 817384
Drug: 2% solution
Normalized name: Lidomar 2% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% solution of sodium cromoglycate (S.C.G.)
Study: 29165105
Drug: TTM-based educational
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTM-based educational program including motivational interviewing, a booklet, and daily SMS.
Study: 20806131
Drug: Neoadjuvant chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiation therapy with subsequent surgery (control arm)
Study: 12566906
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rHuEPO) 10,000 U thrice weekly s.c.
Study: 9078647
Drug: Active dentifrice
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active dentifrice and oral rinse containing sanguinaria extract and zinc chloride
Study: 9078647
Drug: Placebo dentifrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dentifrice and oral rinse
Study: 8103272
Drug: Topical cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporin A (8% w/v) with penetration enhancers (propylene glycol 18% and azone 2%)